0001127602-12-017929.txt : 20120523
0001127602-12-017929.hdr.sgml : 20120523
20120523160503
ACCESSION NUMBER: 0001127602-12-017929
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120326
FILED AS OF DATE: 20120523
DATE AS OF CHANGE: 20120523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BERSTEIN DAVID L
CENTRAL INDEX KEY: 0001242986
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21696
FILM NUMBER: 12864408
MAIL ADDRESS:
STREET 1: C/O ARIAD PHARMACEUTICALS INC
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000884731
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 223106987
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6174940400
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
form4.xml
PRIMARY DOCUMENT
X0305
4
2012-03-26
0000884731
ARIAD PHARMACEUTICALS INC
ARIA
0001242986
BERSTEIN DAVID L
C/O ARIAD PHARMACEUTICALS, INC.
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
1
Senior VP, Chief IP Officer
Common Stock
2012-05-21
4
M
0
26075
4.19
A
263931
D
Common Stock
2012-05-21
4
S
0
26075
16.5445
D
237856
D
Common Stock
2012-03-26
4
S
0
8000
16.00
D
229856
D
Employee Stock Option (Right to Buy)
4.19
2012-05-21
4
M
0
26075
0
D
2003-06-18
2012-06-18
Common Stock
26075
0
D
Shares were acquired upon the exercise of outstanding stock options at $4.19 per share.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.99 to $16.90, inclusive. The reporting person undertakes to provide to ARIAD Pharmaceuticals, Inc. ("ARIAD"), any security holder of ARIAD, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011.
/s/Edward M. Fitzgerald, Attorney-in-Fact
2012-05-22